ESPR Q2 2023 Earnings — Esperion Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

ESPREsperion Therapeutics, Inc.

$577M

Q2 2023 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$26M+36.9% YoY

Gross Profit

$19M73.7% margin

Operating Income

-$37M-143.7% margin

Net Income

-$50M-193.7% margin

EPS (Diluted)

$-0.46

QoQ Revenue Growth

+6.0%

Cash Flow

Operating Cash Flow

-$25M

Free Cash Flow

-$25M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$235M

Total Liabilities

$607M

Stockholders' Equity

-$372M

Cash & Equivalents

$138M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$26M	$19M	+36.9%
Gross Profit	$19M	$10M	+96.6%
Operating Income	-$37M	-$52M	+29.2%
Net Income	-$50M	-$66M	+24.7%

Revenue Segments

Product

$20M79%

Collaboration Revenue

$5M21%